Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. bit.ly/4dw82KX

Our paper on genomic profiling of high-risk smouldering myeloma now in Clinical Cancer Research - Ben Diamond, MD
Sylvester Comprehensive Cancer Center Diko Kazandjian Bachisio Ziccheddu Patrick Blaney Monika Chojnacka Michael Durante Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Gad Getz Laboratory
oncodaily.com/55578.html

#Cancer #Cancer Research #OncoDaily #Oncology

Our work on spatial transcriptomic analysis and biomarkers of chemoimmunotherapy outcome in human ES-SCLC is out in Clinical Cancer Research! Thanks to all people involved in this translational study! Luis Paz-Ares
aacrjournals.org/clincancerres/…

Phase 1 study of ARO-HIF2 shows promise in targeting HIF2α for ccRCC treatment, achieving tumor growth inhibition in a subset of patients. Challenges include neurotoxicity & low response rate.
James Brugarolas Clinical Cancer Research OncoAlert #Cancer #oncology Katy Beckermann Brian Rini, MD…

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell carcinoma. Clinical Cancer Research #oncology OncoAlert OncoDaily #CCRCC

OPEN ACCESS:
aacrjournals.org/clincancerres/…

Aromatase Inhibitor-Associated Musculoskeletal Symptoms ( #AIMSS ) often lead to AI discontinuation. Stearns et al evaluate 10 #SNPs but can’t validate their association with AI discontinuation. bit.ly/3JHUDlg Vered Stearns Lynn Henry Joseph A. Sparano, MD

Top advances of the year #Melanoma ! Great work Adnan Khattak on impact of TIL approval, novel strategies targeting PRAME, oncolytic virus as well as neo-/adjuvant strategies such as mRNA individualized neoAg therapy. Quick read to stay UTD!
acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

CAR and TCR T-cells with membrane-tethered IL-15/21 and solid tumor efficacy. bit.ly/3WeZqlP

Was awesome having Dr. Lewis Lanier (UCSF) present the third annual Dr. Christine Biron Lecture at Brown University this week and giving the history of NK cells - from their slow start to their meteoric rise! AAI MMI_Brown

Phase 1 Study: Acapatamab in mCRPC. bit.ly/3WfDVkI

Clinical Study: Pooled safety analysis of the FGFR1–4 inhibitor futibatinib. bit.ly/3xX0rov

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile. bit.ly/3QmlaID

IL-15 and IL-21: Better when membrane-tethered together on anti-tumor T cells. bit.ly/3Ud6A7r

Want to learn more about CMS4 #coloncancer ? Read our review just published in Clinical Cancer Research aacrjournals.org/clincancerres/… Centre de Recherche des Cordeliers SIRIC CARPEM Hôpital européen Georges-Pompidou AP-HP Université Paris Cité Laurent-Puig Julien Taieb

Thanks AACR for the profile. Hope all #immunotherapy & #immunology interested folks will join the Cancer Immunology Working Group (CIMM), particularly on LinkedIn for on-going discussions of the field!

That's a pretty cover for the April 15th issue of Clinical Cancer Research!

Our latest review article in Clinical Cancer Research online ahead of print ➡️ New means and challenges in the targeting of BTK! 🙌 Check it out to get an update on #CLLsm #lymsm #leusm new drugs targeting BTK and new biology of BTKi resistance! #PrecisionOncology aacrjournals.org/clincancerres/…

Hot off the press Clinical Cancer Research a 3-arm study in which women with CIN-2 or 3 are either observed, treated with intravaginal imiquimod, or treated with an HPV vaccine and imiquimod from Alessandro Santin, et al. Yale School of Medicine Yale Cancer Center. bit.ly/3vCR3FV AACR

Just published at #AACR24 , Küçükosmanoglu, Bart Westerman et al. use adverse event data from the FDA Adverse Event Reporting System to identify patterns of toxicity in drug combinations. bit.ly/3VUoyy2 AACR